ANUH PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 248.2 INR | -2.86% |
|
+3.82% | +70.53% |
| 04-08 | Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023 | CI |
| 04-04 | Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer | CI |
| Sales 2022 | 4.87B 58.34M 4.66B | Sales 2023 | 5.27B 63.24M 5.05B | Capitalization | 3.99B 47.84M 3.82B |
|---|---|---|---|---|---|
| Net income 2022 | 306M 3.67M 293M | Net income 2023 | 362M 4.34M 346M | EV / Sales 2022 | 0.84 x |
| Net cash position 2022 | 210M 2.52M 201M | Net cash position 2023 | 522M 6.25M 499M | EV / Sales 2023 | 0.66 x |
| P/E ratio 2022 |
14.1
x | P/E ratio 2023 |
11
x | Employees | 159 |
| Yield 2022 |
2.04% | Yield 2023 |
2.51% | Free-Float | 30.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.17% | ||
| 1 week | +3.82% | ||
| Current month | +1.79% | ||
| 1 month | -2.48% | ||
| 3 months | +50.29% | ||
| 6 months | +93.42% | ||
| Current year | +70.53% |
1 week
232.55
261.00
1 month
215.30265.00
Current year
155.00265.00
1 year
86.00265.00
3 years
77.00265.00
5 years
48.70265.00
10 years
24.50265.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vivek Bipin Shah
CEO | Chief Executive Officer | 38 | 31/03/17 |
| Chief Executive Officer | 43 | - | |
| Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 06/03/49 | |
| Director/Board Member | 78 | 28/10/80 | |
| Chief Executive Officer | 43 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 248.2 | -2.86% | 46 361 |
| 26/04/24 | 255.6 | +1.57% | 119,438 |
| 25/04/24 | 251.6 | +6.59% | 185,090 |
| 24/04/24 | 236 | -0.25% | 34,895 |
| 23/04/24 | 236.6 | -1.72% | 41,240 |
Delayed Quote Bombay S.E., April 29, 2024 at 09:44 am
More quotes
Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +70.53% | 154M | |
| +21.01% | 43.34B | |
| +20.44% | 21.96B | |
| +11.53% | 14.09B | |
| +13.02% | 13.64B | |
| +39.22% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- ANUHPHR6 Stock
